Form 8-K - Current report:
SEC Accession No. 0001140361-21-028700
Filing Date
2021-08-17
Accepted
2021-08-17 17:29:17
Documents
14
Period of Report
2021-08-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10028124_8k.htm   iXBRL 8-K 29835
2 EXHIBIT 99.1 brhc10028124_ex99-1.htm EX-99.1 313867
6 image0.jpg GRAPHIC 83818
  Complete submission text file 0001140361-21-028700.txt   614451

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btx-20210816.xsd EX-101.SCH 3929
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20210816_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20210816_pre.xml EX-101.PRE 16047
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10028124_8k_htm.xml XML 4402
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 211184176
SIC: 2834 Pharmaceutical Preparations